| Ytd | 38.77% | |
| 1y | 142.72% |
| Open | 39.28 | Prev Close | 39.50 | Low | 37.88 | High | 39.48 | Mkt Cap | 1.81B |
| Vol | 448.20K | Avg Vol | 442.87K | EPS | -0.53 | P/E | N/A | Forward P/E | -19.93 |
| Beta | 2.30 | Short Ratio | 6.01 | Inst. Own | 98.98% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 38.09 | 200-d Avg | 30.25 | 1yr Est | 54.22 |
SEPN News
VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Septerna, Inc. (NASDAQ: SEPN) d
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), today
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a cli
Septerna, Inc. has surged >315% since May 2025, driven by its GPCR-focused drug discovery and a high
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clin
JP Morgan analyst Tessa Romero maintains Septerna (NASDAQ:SEPN) with a Overweight and raises the
Jones Trading analyst Catherine Novack maintains Septerna (NASDAQ:SEPN) with a Buy and raises the
Wells Fargo analyst Derek Archila maintains Septerna (NASDAQ:SEPN) with a Overweight and raises t
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Septerna (NASDAQ:SEPN) with a Buy an
Guggenheim analyst Seamus Fernandez maintains Septerna (NASDAQ:SEPN) with a Buy and raises the pr
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus E
Septerna (NASDAQ:SEPN) reported quarterly losses of $(0.29) per share which beat the analyst consens
US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earni
Samira Shaikhly sold 11,798 shares of Common Stock on May 26, 2026, for a transaction value of ~$355
Guggenheim analyst Seamus Fernandez maintains Septerna (NASDAQ:SEPN) with a Buy and lowers the pr
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Septerna (NASDAQ:SEPN) with a Buy a
Truist Securities analyst Srikripa Devarakonda maintains Septerna (NASDAQ:SEPN) with a Buy and ra
15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted avera
Raymond James analyst Martin Auster maintains Septerna (NASDAQ:SEPN) with a Strong Buy and raises
Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G prote
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotec
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Septerna (NASDAQ:SEPN) with a Buy a
Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus E
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development
SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clini
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Septerna (NASDAQ:SEPN) with a Buy a
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-47
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-47
JP Morgan analyst Tessa Romero maintains Septerna (NASDAQ:SEPN) with a Overweight and raises the
Truist Securities analyst Srikripa Devarakonda maintains Septerna (NASDAQ:SEPN) with a Buy and ra
Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may from time to time issue, in one or mor
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus E
Septerna (NASDAQ:SEPN) reported quarterly losses of $(0.24) per share which missed the analyst conse
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development
Wells Fargo analyst Derek Archila maintains Septerna (NASDAQ:SEPN) with a Overweight and raises t
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Septerna (NASDAQ:SEPN) with a Buy an
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, wi
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clin
Septerna, Inc. (NASDAQ: SEPN - Get Free Report)'s stock price traded down 5.9% during trading on Fri
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clin
